With lean staff, low cash, Axcella races ahead with Long Covid drug


Axcella Therapeutics Inc. has one of the most advanced potential drugs for Long Covid in the industry. It also has only enough cash runway to get it through the second quarter of this year, making for a mad-dash effort to get that drug through clinical trials.

Previous Former Vanderbilt estate in the Berkshires sold, eyed as a potential hotel
Next KFC Foundation partners with Western Governors University to offer free tuition to employees